DAKLINZA

This brand name is authorized in Brazil, Estonia, Hong Kong, Lithuania, Poland, Singapore

Active ingredients

The drug DAKLINZA contains one active pharmaceutical ingredient (API):

1 Daclatasvir UNII LI2427F9CI - DACLATASVIR

Daclatasvir is an inhibitor of nonstructural protein 5A (NS5A), a multifunctional protein that is an essential component of the HCV replication complex. Daclatasvir inhibits both viral RNA replication and virion assembly. Read about Daclatasvir

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AP07		J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AP Antivirals for treatment of HCV infections
Discover more medicines within J05AP07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 505115030021402, 505115030021502, 505115120021702
Country: EE	Ravimiamet	Identifier(s): 1662601, 1662612, 1722596
Country: HK	Department of Health Drug Office	Identifier(s): 64505
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1074203, 1074204, 1074205, 1074206, 1080851, 1080852
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100323527, 100323533
Country: SG	Health Sciences Authority	Identifier(s): 14804P, 14805P